Thank you for posting this article. In terms of Leronlimab getting to become front page news quickly, it is incredibly important that data from the mild to moderate trial be submitted to the FDA as soon as possible. The article reminds all of us that at the moment, Leronlimab has that particular lane all to itself. And that lane is huge! So, this is very likely why NP said on last Monday's investors call that he was very focused on moving that trial along even if it means slowing up a little on the critically ill trial.